Please provide your email address to receive an email when new articles are posted on . Orforglipron is a once-daily oral GLP-1 receptor agonist that can be taken without food or water restrictions.
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...
Foundayo will be available via LillyDirect beginning April 6, with widespread availability through retail pharmacies and telehealth providers occurring soon after. The Food and Drug Administration ...
Indication requires concomitant reduced-calorie diet and increased physical activity for long-term weight loss and maintenance in obesity or overweight with ≥1 weight-related comorbidity. ATTAIN ...
Over the past week, everyone has had launches on the brain — thanks largely to the Artemis II rocket and its ongoing lunar flyby mission. However, there are a couple of health-related launches that ...
Eli Lilly (NYSE: LLY) won the approval it sought when the FDA authorized the company’s oral obesity drug Foundayo™ (orforglipron), but the pharma giant’s post-approval stock bounce was short-lived.
Welcome, and thank you for standing by. I would like to inform all participants that this conference call as well as any Q&A may be recorded and made available to clients of JPMorgan. Where a company ...
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects Kelowna, British Columbia – April 7, 2026 -TheNewswire– Lexaria Bioscience ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s obesity pill ...
Share on Pinterest The FDA has approved a new once-daily GLP-1 pill for weight loss. Image Credit: Healthline/Photo by Eli Lilly Federal regulators have approved the GLP-1 tablet Foundayo for use in ...
WASHINGTON - One of the most common concerns about GLP-1 medications like Ozempic and Wegovy is what happens when you stop taking them. Earlier clinical trials painted a stark picture: stop the drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results